Short answer: a handful of compounds - BPC-157, the CJC-1295 / ipamorelin pairing, Semax and Selank, TB-500, and melanotan II - dominate peptide search and trade-press interest in 2026. This page maps that interest neutrally. Where a third-party article describes “benefits,” we attribute it explicitly. Popularity is a demand signal, not proof of efficacy or approval, and nothing here is a recommendation for human use.
Industry trend pieces - for example OptiMantra’s 2026 round-up of in-demand peptides - are useful as a read on what people are searching for and discussing. They are written for a clinical-services audience, so their benefit language reflects that source, not the position of a research-reagent supplier. We reproduce the map of interest while keeping a hard line: New-U makes no human-use, efficacy or dosing claims about any compound below.
How to read this page. Each entry states (a) what the compound is, in neutral biochemical terms, and (b) what third-party trend commentary says interest centres on - clearly attributed. None of (b) is asserted by New-U as fact or as a reason to use anything in humans. All material is research use only, not for human consumption. General information, not medical advice.
Across 2026 round-ups the same four themes recur: tissue-repair / recovery research, growth-hormone-axis research, neuro / cognitive research, and metabolic research. OptiMantra also emphasises a methodological trend - more structured outcome tracking and personalisation in the clinics that use peptides. We note the clusters purely to organise the landscape, not to endorse any application.
What it is: a synthetic peptide derived from a sequence identified in gastric juice; a long-standing subject of preclinical tissue-repair literature. Reported interest (per OptiMantra): the trend article frames demand around tissue-repair and gut-related research contexts. That is the source’s framing of interest, not a New-U claim. See the neutral science write-up in our BPC-157 research guide.
What it is: two separate compounds frequently studied together in the growth-hormone-secretagogue literature - CJC-1295 as a GHRH analogue, ipamorelin as a selective GH secretagogue. Reported interest: OptiMantra attributes demand to growth-hormone-axis and body-composition research discussion. Both also appear in the 2023 FDA compounding review - a reminder that interest and regulatory caution coexist. Reagent-only guides: CJC-1295, ipamorelin.
What they are: short peptides studied in the neuropeptide / neuromodulation literature, largely in non-Western preclinical and early clinical work. Reported interest: the trend article positions them around cognitive and stress-research discussion. We present them only as research reagents; the evidence base is early and we make no functional claims.
What it is: a synthetic fragment related to thymosin beta-4, a focus of preclinical wound-healing and tissue-repair research. Reported interest: OptiMantra ties demand to musculoskeletal-recovery research interest. Neutral science: TB-500 research guide.
What it is: a synthetic melanocortin-receptor agonist analogue. Reported interest: trend pieces note aesthetic-research discussion. Notably, melanotan II also appears among compounds in the FDA compounding review and clinician cautions - high interest does not imply low risk or approval. Research reagent only.
It means these compounds attract disproportionate search volume, trade-press coverage and laboratory ordering. It does not mean their human efficacy is established, that they are approved, or that the benefit language in trend articles is correct. Much of the literature is preclinical or animal-only - the same evidence gap covered in Are Peptides Safe? New-U lists popular compounds because researchers look for them, and labels every one research use only, not for human consumption.
Which peptides are most discussed in 2026?
Trend write-ups (e.g. OptiMantra) repeatedly name BPC-157, CJC-1295/ipamorelin, Semax, Selank, TB-500 and melanotan II. New-U treats these as reagents only.
Does popularity mean proven or approved?
No. Interest is a demand signal, not evidence. Much underlying data is preclinical/animal-only; third-party benefit language is attributed, not endorsed.
Does New-U recommend human use?
No. All compounds are research use only, not for human consumption, with a CoA and no dosing or medical guidance. General information, not medical advice.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog